Accrol Group Holdings plc is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH products to supply retailers throughout the UK. Accrol imports parent reels from around the world and converts them into finished goods at the Company’s 350,000 sq. ft. manufacturing, storage and distribution facility in Blackburn, Lancashire. Accrol currently manufactures approximately 17 million units per week and supplies some of the UK’s largest retailers.

Accrol Group Holdings plc is listed on AIM, the growth market of the London Stock Exchange.

The Company was incorporated and registered in England and Wales on 30 April 2014 under the Act with registered number 9019496 as a private company limited by shares with the name Aghoco 1220 Limited. The name of the Company was changed to Accrol Group Holdings Limited on 1 August 2014. The Company was re-registered as a public limited company with the name Accrol Group Holdings plc on 1st June 2016. Accrol Group Holdings plc’s main country of operation is the UK.

The Company, and the Group, trade under the name “Accrol Papers”.

In need of news.

Sold my last holding, falling daily.

Probably tick up again in the future .

Put the funds in sron and sold and re-bought. :-)) profit just dwindling for me here.

I wonder if he gets loo rolls free for life. lol


Official opening of new manufacturing facility
RNS
RNS Number : 7352B
Accrol Group Holdings PLC
06 April 2017
 
6 April 2017
 
Accrol Group Holdings plc (the "Company" or "Accrol")
Official opening of new manufacturing facility in Leyland, Lancashire
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces the official opening of its new 168,000 sq. ft. manufacturing facility in Leyland, Lancashire with the unveiling of a ceremonial plaque by Lord Shuttleworth, Lord-Lieutenant of Lancashire.
This facility has had two tissue converting lines installed, which will increase Accrol's total converting capacity to 143,000 tonnes per annum.  Manufacturing began at the end of January 2017 and output will steadily increase as new shift patterns are added over the coming weeks. When both lines are fully manned they will create over 80 new jobs, taking Accrol's total number of employees to almost 600, all of whom are based in Lancashire.  The new facility has space for a further four converting lines.
Steve Crossley, Accrol's CEO, commented, "This new facility marks another milestone in Accrol's development, increasing our total production capacity by 25,000 tonnes to 143,000 tonnes per annum."

ST of IC upgraded his target price today 180p

Trading Update, New Facilities & Notice of Results
RNS
RNS Number : 1805F
Accrol Group Holdings PLC
16 May 2017
 
16 May, 2017
 
This announcement contains inside information
Accrol Group Holdings plc (the "Company" or "Accrol")
Trading Update, New Warehousing and Distribution Facilities and Notice of Results
 
Accrol Group Holdings plc, the AIM-listed leading independent tissue converter, provides the following trading update for the twelve-month period ended 30 April 2017.
The Company has had a strong year of growth in its first year as a publicly listed business following its successful IPO on AIM in June 2016, and is pleased to announce that it has performed in line with market expectations despite some challenging macro-economic factors.
Over the last twelve months, Accrol has consolidated its position as the leading supplier of tissue products to the Discount sector and has continued to invest in its growth plans with the opening of a new 168,000 sq. ft. manufacturing facility in Leyland, Lancashire in January 2017, increasing production capacity to 143,000 tonnes per annum.
The Company is also pleased to announce today that it has agreed a 10-year lease with Orbit Developments on a 368,000 sq. ft. warehouse in West Lancashire.  The warehouse will store finished goods and provide central distribution facilities to all UK customers, enabling Accrol to simplify and consolidate its existing warehouse facilities. Warehouse management and national logistics will be contracted out to NFT.
 
Steve Crossley, Accrol's CEO, commented:
 
"We are pleased to announce that, despite a less favourable macro-economic environment, we have performed in line with expectations in our maiden year as a publicly-listed business. We have continued to make progress with our growth plans, extending our relationships with both new and existing customers and investing in our infrastructure for the future.
 
 
Final results for the year ended 30 April 2017 will be announced on 10 July 2017.
 
Today, the Company will be holding an Investor Day at its Head Office in Blackburn, Lancashire. There will be no material information disclosed that is not already in the public domain.

Large buys going through.

Andrex reduces size of toilet rolls

Yeah it's a bit like all those chocolate bars dream , the ones that's half the size they were .

Good chance for this company. :-))

Finals Monday 10 July

Preliminary results for year ended 30 April 2017
RNS
RNS Number : 5118K
Accrol Group Holdings PLC
10 July 2017
 
This announcement contains inside information
10 July 2017
Accrol Group Holdings plc
Preliminary results for the twelve months ended 30 April 2017
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce its preliminary results for the twelve months to 30 April 2017.
 
Financial Highlights
 
·      Revenue increased 14.2% to £135.1m (FY16: £118.2m)
·      Gross Profit increased 9.3% to £37.7m (FY16: £34.5m)
·      Adjusted gross margin(1) was  27.9% (FY16: 28.1%) supported by favourable parent reel pricing and significant currency hedging
·      Adjusted EBITDA(1) increased 6.8% to £16.1m (FY16: £15.0m)
·      Adjusted profit after tax(1) increased 57.3% to £11.0m (FY16: £7.0m)
·      Profit after tax increased 29.3% to £7.4m (FY16: £5.7m)
·      Continued strong cash generation in a period which included a £3.6m repayment of loan note interest
·      Net debt reduced by £41.7m to £19.0m (Net debt / Adjusted EBITDA reduced from 4.0x to 1.2x)
·      Basic EPS of 9p and adjusted EPS of 12p
·      Final dividend proposed of 4p per ordinary share giving a total of 6p per ordinary share for the full year
 
Operational Highlights
 
·      Successful maiden full year as a publicly listed company, with a solid trading performance
·      New contract wins have seen market share grow to over 50% of the Discount Sector
·      Good progress made in building a platform for future growth
·      Key new hires to operations and management functions
·      Opened new 168,000 sq. ft. manufacturing facility at Leyland, Lancashire, with two tissue converting lines commissioned and a third line expected in FY18
·      Supply Chain Optimisation plan implemented to improve and simplify warehousing and logistics through a 368,000 sq ft. central warehouse at Skelmersdale and managed by NFT Distribution
 
Steve Crossley, Chief Executive Officer of Accrol, commented:
"This has been a year of positive change for Accrol as we have transitioned to life as an AIM listed company. We have won new contracts and increased our share of the Discount Sector to over 50%."
 
"We continue to build a platform for future growth, having made a significant investment in our new manufacturing facility at Leyland to create extra capacity. A new finished goods warehouse in Skelmersdale, announced in May 2017, will provide central storage and distribution facilities for our customers, improving our supply chain efficiency and enabling us to build on our market position."
 
"Increasing input costs, driven by exchange rates, are impacting most product categories in UK retail and like all UK manufacturers, we continue to seek inflation recovery. There are positive signs, with some retailers increasing consumer price points, although it is slower than we expected. We believe that as price increases come through fully in the market, this will continue to drive shoppers to seek good value in the Discount and Multiple own-label sectors.''
Note 1: Non-GAAP measures are reconciled in note 25
 
There will be an analyst presentation to discuss the results at 9am on 10th July 2017 at the offices of Camarco. Analysts interested in attending should contact Kimberley Taylor on +44 203 757 4999.
 
The Company's annual report for the year ended 30 April 2017 (including notice of the annual general meeting to be held at Accrol's Head Office in Blackburn on 6th October 2017 at 2pm) (the "Annual Report") will shortly be available for downloading from the Company's web site at http://www.accrol.co.uk/investor-relations/.

08:40 10/07/2017
Broker Forecast - Liberum Capital issues a broker note on Accrol Group Hldgs Plc
Liberum Capital today initiates coverage of Accrol Group Hldgs Plc (LON:ACRL) with a buy investment rating and price target of 200p. Story provided by StockMarketWire.com

Someone elsewhere mentioned that this stock is tipped in Shares magazine this week. Not seen it myself.

Full page (page12 ) juzzle

Simon Thompson on investor's chronicle wrote, in answer to a reader comment the other day, that "I am publishing an update on Accrol on Monday 24 July."

(posted by glawsiain elsewhere)

Thanks, will e interesting to read. Shares seems to think there will be plenty of upside.

Haven't seen that Simon Thompson update yet. Not among this latest search on Google News: Accrol news

EDIT: I found this analysis of Accrol's Return On Equity interesting: R-o-E, Accrol

cheers juzzle